Prospective monitoring of individuals identified with high rates of MLH1 promoter methylation and assessing the presence of MLH1 promoter methylation in HPCs prior to or early in disease evolution would be necessary to definitively illustrate the clinical relevance of MLH1 promoter methylation on the evolution of hematologic disorders. This evidence concerns the gene MLH1 and hematologic disorder.